Category: Alzheimer's/Dementia

Life Serotonin Supplementation Update: UK Microdosing LSD and Serotonin Receptors

4/19/2017

Serotonin Receptor by S Jahnichen

A 10 April 2017 BBC story, Microdosing: The people taking LSD with their breakfast, reports individuals regularly taking small amounts of LSD for health.

A look at “serotonin” on Wikipedia reveals why people would be supplementing their serotonin systems for health:

Serotonin Receptor Actions/Modulations

Memory
Learning
Anxiety
Depression
Schizophrenia
Regulating the release of serotonin
Analgesia
Aggression
Dopamine release in prefrontal cortex
Vasoconstriction
Bone mass
Psychedelia [note: “Physiodelia” is often a better word]
Norepinephrine release
Glutamate release in prefrontal cortex
Urinary bladder contractions
Cardiovascular functioning
Empathy (via the spindle neurons)
Dopamine release into the mesocorticolimbic pathway
Acetylcholine [nicotinic] release in prefrontal cortex
Appetite
Anti-psychotic
Emesis
Anxiolysis [calming]
Movement of food across the GI tract
Memory consolidation
Cognition

One could easily add laughter, dreams (day and night), prayer and meditation to things our serotonin receptors modulate.

*Next Up: 26 April and a Life Serotonin Supplementation (LSS) on Physiodelia.

Posted by Bryan W. Brickner

0 Comments

Homeostasis: Publius’ (Ultralow) THC Political Cannabinoid Science

9/5/2014

0 Comments

The Cannabis Papers by Publius

The Cannabis Papers: A citizen’s guide to cannabinoids (2011)
By Publius

Welcome Homeostasis!
Burning Man Edition

Today’s science roundup looks at four 2014 articles on how the cannabinoid system (CS) modulates our health through homeostasis. The line-up links to CS PubMed articles discussing: hippocampus inhibition and excitation, pain relief from a Chinese herb (thunder God vine), GABA pain dis-inhibition, and brain protection from a single ultralow dose of tetrahydrocannabinol (THC).

The annual Burning Man festival in Black Rock City (NV) was last week; participants test their CS by enduring two Black Rock extremes ~ art and nature ~ which create space for mind and body to catch a glimpse of … spirit.

I. Hippocampus Homeostasis (Inhibition and Excitation) and the CS (Endos)
“Endocannabinoids (eCBs) modulate both excitatory and inhibitory neurotransmission in hippocampus via activation of pre-synaptic cannabinoid receptors. Here, we present a model for cannabinoid mediated short-term depression of excitation (DSE) based on our recently developed model for the equivalent phenomenon of suppressing inhibition (DSI). … Finally, we explore under which conditions the combination of DSI and DSE can temporarily shift the fine balance between excitation and inhibition. This highlights a mechanism by which eCBs might act in a neuro-protective manner during high neural activity.”
Cannabinoid-mediated short-term plasticity in hippocampus.
Zachariou M, Thul R.
J Comput Neurosci. 2014 Aug 16. [Epub ahead of print]
PMID: 25123173 [PubMed - as supplied by publisher]
Related citations

II. Homeostasis (Pain Relief) and CS CB2 Signaling
“Celastrol, a major active ingredient of Chinese herb Tripterygium wilfordii Hook. f. (thunder god vine), has exhibited a broad spectrum of pharmacological activities, including anti-inflammation, anti-cancer and immunosuppression. … Taken together, our results demonstrate the analgesia effects of celastrol through CB2 signaling and propose the potential of exploiting celastrol as a novel candidate for pain relief.”
Celastrol attenuates inflammatory and neuropathic pain mediated by cannabinoid receptor type 2.
Yang L, Li Y, Ren J, Zhu C, Fu J, Lin D, Qiu Y.
Int J Mol Sci. 2014 Aug 6;15(8):13637-48. doi: 10.3390/ijms150813637.
PMID: 25101848 [PubMed - in process] Free Article
Related citations

III. Homeostasis (GABA Pain Dis-inhibition) and the CS
“At the cellular level, opioids and cannabinoids are hypothesised to activate descending analgesia through an indirect process of 'GABA disinhibition'-suppression of inhibitory GABAergic inputs onto output neurons which constitute the descending analgesic pathway.”
Descending modulation of pain: the GABA disinhibition hypothesis of analgesia.
Lau BK, Vaughan CW.
Curr Opin Neurobiol. 2014 Jul 24;29C:159-164. doi: 10.1016/j.conb.2014.07.010. [Epub ahead of print] Review.
PMID: 25064178 [PubMed - as supplied by publisher]
Related citations

IV. Homeostasis (CS CNS Protection) from a Single Ultralow Dose of THC
“In our previous studies, we found that a single ultralow dose of tetrahydrocannabinol (THC; 0.002 mg/kg, three to four orders of magnitude lower than the conventional doses) protects the brain from different insults that cause cognitive deficits. … Our results suggest that an ultralow dose of THC that lacks any psychotrophic activity protects the brain from neuroinflammation-induced cognitive damage and might be used as an effective drug for the treatment of neuroinflammatory conditions, including neurodegenerative diseases.”
Ultralow doses of cannabinoid drugs protect the mouse brain from inflammation-induced cognitive damage.
Fishbein-Kaminietsky M, Gafni M, Sarne Y.
J Neurosci Res. 2014 Jul 16. doi: 10.1002/jnr.23452. [Epub ahead of print]
PMID: 25042014 [PubMed - as supplied by publisher]
Related citations

Video: Cannabinoid Profiles - THC, THCA, THCV, CBD, CBG, CBN, CBC & Terpenes

Once Upon A Time ...

Posted by Bryan W. Brickner

0 Comments

Homeostasis: Publius’ Alcohol Political Cannabinoid Science

8/30/2014

3 Comments

The Cannabis Papers by Publius (2011)

The Cannabis Papers: A citizen’s guide to cannabinoids (2011)

By Publius

Today’s science roundup looks at four articles on how the cannabinoid system (CS) modulates our health through homeostasis ~ including one on the de-homeostatic (harmful) effects caused by chronic alcohol use on one’s CS. The line-up links to 2014 PubMed articles discussing: heteromerization, chronic alcohol harms, sensory information salience and stress response attenuation.

I. Heteromerization (GPR55 and CB2) and the CS
“In HEK293 cells expressing GPR55 and cannabinoid CB2 R receptors, heteromers that are unique signaling units are formed. The signaling by agonists of either receptor is governed i) by the presence or absence of the partner receptors (with the consequent formation of heteromers) and ii) by the activation state of the partner receptor.”
Heteromerization of GPR55 and cannabinoid CB2 receptors modulates signaling.
Balenga NA, Martínez-Pinilla E, Kargl J, Schröder R, Peinhaupt M, Platzer W, Bálint Z, Zamarbide M, Dopeso-Reyes I, Ricobaraza A, Pérez-Ortiz JM, Kostenis E, Waldhoer M, Heinemann A, Franco R.
Br J Pharmacol. 2014 Jul 22. doi: 10.1111/bph.12850. [Epub ahead of print]
PMID: 25048571 [PubMed - as supplied by publisher]
Related citations

II. De-Homeostasis (Chronic Alcohol Use) and the CS
“Chronic use of alcohol is associated with structural and functional alterations in brain areas that subserve cognitive processes. Of particular importance is the prefrontal cortex (PFC) that is involved in higher order behaviors such as decision making, risk assessment and judgment. … Overall, these results suggest that ethanol's down-regulation of cannabinoid signaling results in altered network activity in the prefrontal cortex.”
Chronic ethanol alters network activity and endocannabinoid signaling in the prefrontal cortex.
Pava MJ, Woodward JJ.
Front Integr Neurosci. 2014 Jul 18;8:58. doi: 10.3389/fnint.2014.00058. eCollection 2014.
PMID: 25100953 [PubMed] Free Article
Related citations

III. Homeostasis (Sensory Information) and the CS
“Emerging evidence from both basic and clinical research demonstrates an important role for endocannabinoid (ECB) signaling in the processing of emotionally salient information, learning, and memory. Cannabinoid transmission within neural circuits involved in emotional processing has been shown to modulate the acquisition, recall, and extinction of emotionally salient memories and importantly, can strongly modulate the emotional salience of incoming sensory information.”
The role of cannabinoid transmission in emotional memory formation: implications for addiction and schizophrenia.
Tan H, Ahmad T, Loureiro M, Zunder J, Laviolette SR.
Front Psychiatry. 2014 Jun 30;5:73. doi: 10.3389/fpsyt.2014.00073. eCollection 2014. Review.
PMID: 25071606 [PubMed] Free PMC Article
Related citations

IV. Homeostasis (Stress Response) and the CS
“Endocannabinoids are produced on demand and function to attenuate many of the physiological effects of the stress response. The endocannabinoid system is made up of cannabinoid receptors, the fatty acid signaling molecules that bind to and activate these receptors, and the enzymes that synthesize and catabolize these endocannabinoid signaling molecules.”
The endocannabinoid system modulates stress, emotionality, and inflammation.
Crowe MS, Nass SR, Gabella KM, Kinsey SG.
Brain Behav Immun. 2014 Jun 19. pii: S0889-1591(14)00172-X. doi: 10.1016/j.bbi.2014.06.007. [Epub ahead of print] Review.
PMID: 24953427 [PubMed - as supplied by publisher]
Related citations

Brain Video:
Why Do Some People Become Alcoholics?

Posted by Bryan W. Brickner

3 Comments

Alzheimer’s, Cancer and Homeostatic Cannabinoid Science

6/29/2014

0 Comments

The Cannabis Papers by Publius (2011)

The Cannabis Papers: A citizen’s guide to cannabinoids (2011)
By Publius

The CS World Cup: Goaltender Edition

Today, tending to the goals of mediating Alzheimer’s and preventing carcinogenesis, Publius spotlights two June abstracts from PubMed on the homeostatic cannabinoid system (CS). For Alzheimer’s disease it is CS modulation of cognitive decline; for preventing carcinogenesis the findings unveil a previously unknown CS signaling platform: CB2-GPR55 receptor heteromers.

I. CS Mediates Cognitive Decline In Alzheimer's Disease

Set: “It has been widely reported that β-amyloid peptide (Aβ) blocks long-term potentiation (LTP) of hippocampal synapses. Here, we show evidence that Aβ more potently blocks the potentiation of excitatory postsynaptic potential (EPSP)-spike coupling (E-S potentiation). This occurs, not by direct effect on excitatory synapses or postsynaptic neurons, but rather through an indirect mechanism: reduction of endocannabinoid-mediated peritetanic disinhibition.”

Setting: “During high-frequency (tetanic) stimulation, somatic synaptic inhibition is suppressed by endocannabinoids. We find that Aβ prevents this endocannabinoid-mediated disinhibition, thus leaving synaptic inhibition more intact during tetanic stimulation.”

Science: “This intact inhibition opposes the normal depolarization of hippocampal pyramidal neurons that occurs during tetanus, thus opposing the induction of synaptic plasticity. Thus, a pathway through which Aβ can act to modulate neural activity is identified, relevant to learning and memory and how it may mediate aspects of the cognitive decline seen in Alzheimer's disease.”
β-Amyloid Inhibits E-S Potentiation through Suppression of Cannabinoid Receptor 1-Dependent Synaptic Disinhibition.
Orr AL, Hanson JE, Li D, Klotz A, Wright S, Schenk D, Seubert P, Madison DV.
Neuron. 2014 Jun 18;82(6):1334-45. doi: 10.1016/j.neuron.2014.04.039.
PMID: 24945775 [PubMed - in process]
Related citations

II. CS Oncology Signaling Unveiled: Evidence of Previously Unknown Platforms

Set: “The G protein-coupled receptors CB2 (CB2R) and GPR55 are overexpressed in cancer cells and human tumors. As a modulation of GPR55 activity by cannabinoids has been suggested, we analyzed whether this receptor participates in cannabinoid effects on cancer cells.”

Setting: “Here, we show that CB2R and GPR55 form heteromers in cancer cells, that these structures possess unique signaling properties, and that modulation of these heteromers can modify the antitumoral activity of cannabinoids in vivo.”

Science: “These findings unveil the existence of previously unknown signaling platforms that help explain the complex behavior of cannabinoids and may constitute new targets for therapeutic intervention in oncology.”
Targeting CB2-GPR55 Receptor Heteromers Modulates Cancer Cell Signaling.
Moreno E, Andradas C, Medrano M, Caffarel MM, Pérez-Gómez E, Blasco-Benito S, Gómez-Cañas M, Pazos MR, Irving AJ, Lluís C, Canela EI, Fernández-Ruiz J, Guzmán M, McCormick PJ, Sánchez C.
J Biol Chem. 2014 Jun 18. pii: jbc.M114.561761. [Epub ahead of print]
PMID: 24942731 [PubMed - as supplied by publisher] Free Article
Related citations

Video: Homeostasis 1, Physiological Principles ~ Dr. John Campbell

Posted by Bryan W. Brickner

0 Comments

Passing the Alzheimer’s Test and One’s Cannabinoid System ~ An Update

5/29/2014

0 Comments

In March we noted the relentless strength of Alzheimer’s disease ~ and it’s still going strong. Good thing so is the science. Here are five more 2014 National Institutes of Health (PubMed) research updates on Alzheimer’s disease and cannabinoids.

The researchers in the third piece below make an interesting point concerning time; seems there haven’t been enough “adequately powered trials” on the safety of cannabinoids in older test subjects. That is harmful and a symptom of our polity.

Talk cannabinoids please … waiting another generation is not acceptable.

I.
Cannabinoid receptor-dependent metabolism of 2-arachidonoylglycerol during aging.
Pascual AC, Gaveglio VL, Giusto NM, Pasquaré SJ.
Exp Gerontol. 2014 Jul;55:134-42. doi: 10.1016/j.exger.2014.04.008. Epub 2014 Apr 24.
PMID: 24768821 [PubMed - in process]
Related citations

II.
Cannabinoids for pain in dementia: the good, the bad, and the ugly.
Ahmed AI, van den Elsen GA, van der Marck MA, Olde Rikkert MG.
J Am Geriatr Soc. 2014 May;62(5):1001-2. doi: 10.1111/jgs.12817. No abstract available.
PMID: 24828945 [PubMed - in process]
Related citations

III.
Efficacy and safety of medical cannabinoids in older subjects: a systematic review.
van den Elsen GA, Ahmed AI, Lammers M, Kramers C, Verkes RJ, van der Marck MA, Rikkert MG.
Ageing Res Rev. 2014 Mar;14:56-64. doi: 10.1016/j.arr.2014.01.007. Epub 2014 Feb 5.
PMID: 24509411 [PubMed - in process]
Related citations

IV.
Parsing the players: 2-arachidonoylglycerol synthesis and degradation in the CNS.
Murataeva N, Straiker A, Mackie K.
Br J Pharmacol. 2014 Mar;171(6):1379-91. doi: 10.1111/bph.12411.
PMID: 24102242 [PubMed - in process]
Related citations

V.
Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease.
González-Naranjo P, Pérez-Macias N, Campillo NE, Pérez C, Arán VJ, Girón R, Sánchez-Robles E, Martín MI, Gómez-Cañas M, García-Arencibia M, Fernández-Ruiz J, Páez JA.
Eur J Med Chem. 2014 Feb 12;73:56-72. doi: 10.1016/j.ejmech.2013.11.026. Epub 2013 Dec 7.
PMID: 24378710 [PubMed - in process]
Related citations

VI.
Video ~ Holistic Alzheimer’s Video: Cannabis Oil and Medical Marijuana

Posted by Bryan W. Brickner

0 Comments

Indiscernible Cannabinoid Science ~ Publius’ March 2014 Roundup

3/30/2014

1 Comment

The Cannabis Papers: A citizen’s guide to cannabinoids (2011)
By Publius

Here are seven 2014 findings on how the cannabinoid system (CS) modulates homeostasis and other systems in our bodies: the roundup links to recent PubMed articles on the vanilloid, neurological, dopamine, visual, skeletal, and endocrine systems.

I. Vanilloid System and the CS
“These data indicate that the eCB system can modulate inflammatory activation of the endothelium and may have important implications for a variety of acute inflammatory disorders that are characterized by EC [Endothelial Cell] activation.”
The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells.
Wilhelmsen K, Khakpour S, Tran A, Sheehan K, Schumacher M, Xu F, Hellman J.
J Biol Chem. 2014 Mar 18. [Epub ahead of print]
PMID: 24644287 [PubMed - as supplied by publisher] Free Article
Related citations

II. Neurological System (Migraines) and the CS
“These findings suggest that the pharmacological manipulation of the CB2 receptor may represent a potential therapeutic tool for the treatment of migraine.”
Activation of CB2 receptors as a potential therapeutic target for migraine: evaluation in an animal model.
Greco R, Mangione AS, Sandrini G, Nappi G, Tassorelli C.
J Headache Pain. 2014 Mar 17;15(1):14. doi: 10.1186/1129-2377-15-14.
PMID: 24636539 [PubMed - in process] Free Article
Related citations

III. Dopamine System and the CS
“The endocannabinoid system regulates feeding behavior through a modulatory action on different neurotransmitter systems, including the dopaminergic system.”
Involvement of the Cannabinoid CB1 Receptor in Modulation of Dopamine Output in the Prefrontal Cortex Associated with Food Restriction in Rats.
Dazzi L, Talani G, Biggio F, Utzeri C, Lallai V, Licheri V, Lutzu S, Mostallino MC, Secci PP, Biggio G, Sanna E.
PLoS One. 2014 Mar 14;9(3):e92224. doi: 10.1371/journal.pone.0092224. eCollection 2014.
PMID: 24632810 [PubMed - in process] Free PMC Article
Related citations

IV. Neurological System (Alzheimer’s disease) and the CS
“Moreover, endocannabinoid signaling has been demonstrated to modulate numerous concomitant pathological processes, including neuroinflammation, excitotoxicity, mitochondrial dysfunction, and oxidative stress.”
Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic.
Aso E, Ferrer I.
Front Pharmacol. 2014 Mar 5;5:37. eCollection 2014. Review.
PMID: 24634659 [PubMed - as supplied by publisher] Free PMC Article
Related citations

V. Visual System and the CS
“Our findings provide neurophysiologic evidence for a link between cannabinoid-signaling, network dynamics and the function of a canonical cortical circuit.”
Cannabinoid neuromodulation in the adult early visual cortex.
Ohiorhenuan IE, Mechler F, Purpura KP, Schmid AM, Hu Q, Victor JD.
PLoS One. 2014 Feb 19;9(2):e87362. doi: 10.1371/journal.pone.0087362. eCollection 2014.
PMID: 24586271 [PubMed - in process] Free PMC Article
Related citations

VI. Skeletal System (Osteoarthritis) and the CS
“The ubiquitous distribution of cannabinoid receptors, together with the physiological role of the endocannabinoid system in the regulation of pain, inflammation and even joint function further support the therapeutic interest of cannabinoids for osteoarthritis.”
Involvement of the endocannabinoid system in osteoarthritis pain.
La Porta C, Bura SA, Negrete R, Maldonado R.
Eur J Neurosci. 2014 Feb;39(3):485-500. doi: 10.1111/ejn.12468.
PMID: 24494687 [PubMed - in process]
Related citations

VII. Endocrine System (HP-axis) and the CS
“Since the endocannabinoid system components are present at sites involved in the hypothalamic-pituitary axis regulation, several studies were performed in order to investigate the endocannabinoid-mediated neurotransmitters and hormones secretion under physiological and pathological conditions.”
Role of the Endocannabinoid System in the Neuroendocrine Responses to Inflammation.
De Laurentiis A, Araujo HA, Rettori V.
Curr Pharm Des. 2014 Jan 30. [Epub ahead of print]
PMID: 24588819 [PubMed - as supplied by publisher]
Related citations

~’~
posted by bwb

1 Comment

Passing the Alzheimer’s Test Involves One’s Cannabinoid System

3/28/2014

0 Comments

Here are five “more” 2014 National Institutes of Health (PubMed) research updates on Alzheimer’s disease and cannabinoids. I mention “more” because of the widely reported research this month, Plasma Phospholipids Identify Antecedent Memory Impairment in Older Adults.

CNN noted the plasma science as Blood test predicts Alzheimer’s disease.

Forbes saw the ability to identify memory impairment before its onset (by measuring various lipids/fats in blood) as double-edged: How A New Alzheimer’s Test Could Kill Long-Term Care Insurance – Or Make It Cheaper.

I also say “more” because this isn’t new news. The sixth item included is a video of CNN Int., reported in March 2008, on how cannabis may be “a boon to Alzheimer’s patients.”

While we wait for the boon (and it has to be a political boon now), the progression of the disease doesn’t. We’d be wise to mimic the strength of Alzheimer’s disease in our resolve to understand its causes and to offer relief: the disease is relentless … we aught to be as well.

I.
The influence of cannabinoids on generic traits of neurodegeneration.
Fagan SG, Campbell VA.
Br J Pharmacol. 2014 Mar;171(6):1347-60. doi: 10.1111/bph.12492.
PMID: 24172185 [PubMed - in process]
Related citations

II.
Cannabinoids for treatment of Alzheimer's disease: moving toward the clinic.
Aso E, Ferrer I.
Front Pharmacol. 2014 Mar 5;5:37. eCollection 2014. Review.
PMID: 24634659 [PubMed - as supplied by publisher] Free PMC Article
Related citations

III.
In vivo type 1 cannabinoid receptor availability in Alzheimer's disease.
Ahmad R, Goffin K, Van den Stock J, De Winter FL, Cleeren E, Bormans G, Tournoy J, Persoons P, Van Laere K, Vandenbulcke M.
Eur Neuropsychopharmacol. 2014 Feb;24(2):242-50. doi: 10.1016/j.euroneuro.2013.10.002. Epub 2013 Oct 17.
PMID: 24189376 [PubMed - in process]
Related citations

IV.
Altered Expression of the CB1 Cannabinoid Receptor in the Triple Transgenic Mouse Model of Alzheimer's Disease.
Bedse G, Romano A, Cianci S, Lavecchia AM, Lorenzo P, Elphick MR, Laferla FM, Vendemiale G, Grillo C, Altieri F, Cassano T, Gaetani S.
J Alzheimers Dis. 2014 Feb 4. [Epub ahead of print]
PMID: 24496074 [PubMed - as supplied by publisher]
Related citations

V.
Brain Innate Immunity In The Regulation Of Neuroinflammation: Therapeutic Strategies By Modulating Cd200-Cd200r Interaction Involve The Cannabinoid System.
Hernangomez M, Carrillo-Salinas FJ, Mecha M, Correa F, Mestre L, Loria F, Feliu A, Docagne F, Guaza C.
Curr Pharm Des. 2014 Jan 30. [Epub ahead of print]
PMID: 24588829 [PubMed - as supplied by publisher]
Related citations

VI.
Video Archives ~ CNN Int. March 2008 (B4-Obama)
Medical Marijuana Alzheimer, CNN Int. 11 Mar 2008
“Drug could be a boon to Alzheimer’s patients.”

Bryan W. Brickner

0 Comments

Indiscernible Cannabinoid System Science ~ Publius’ February 2014 Roundup

2/27/2014

0 Comments

The Cannabis Papers: A citizen’s guide to cannabinoids (2011)
By Publius

This roundup links to seven 2014 PubMed articles on cannabinoids modulating other systems in our bodies, such as: the olfactory, endocrine, vanilloid, serotonin, opioid, dopamine, and nervous systems. There’s also a bit of systemic science ~ getting a good night’s sleep.

I. Olfactory System and CS
“Thus, CB1 receptor-dependent control of cortical feedback projections in olfactory circuits couples internal states to perception and behavior.”

The endocannabinoid system controls food intake via olfactory processes.
Soria-Gómez E, Bellocchio L, Reguero L, Lepousez G, Martin C, Bendahmane M, Ruehle S, Remmers F, Desprez T, Matias I,
Wiesner T, Cannich A, Nissant A, Wadleigh A, Pape HC, Chiarlone AP, Quarta C, Verrier D, Vincent P, Massa F, Lutz B,
Guzmán M, Gurden H, Ferreira G, Lledo PM, Grandes P, Marsicano G.
Nat Neurosci. 2014 Mar;17(3):407-15. doi: 10.1038/nn.3647. Epub 2014 Feb 9.
PMID: 24509429 [PubMed - in process]

II. Endocrine System (Hypothalamus-pituitary axis) and CS
“Whereas the effect on 3β-HSD was counteracted by SR141716A (Rimonabant) - a selective antagonist of CB1, thus indicating a CB1 dependent modulation - the effect on cyp17 was not, suggesting a possible involvement of receptors other than CB1, probably the type-1 vanilloid receptor (TRPV1), since AEA works as an endocannabinoid and an endovanilloid as well.”

Hypothalamus-pituitary axis: an obligatory target for endocannabinoids to inhibit steroidogenesis in frog testis.
Chianese R, Ciaramella V, Fasano S, Pierantoni R, Meccariello R.
Gen Comp Endocrinol. 2014 Feb 21. pii: S0016-6480(14)00053-7. doi: 10.1016/j.ygcen.2014.02.010. [Epub ahead of print]
PMID: 24566122 [PubMed - as supplied by publisher]

III. Vanilloid System (Schizophrenia) and CS
“Our results indicate that the schizophrenia-like behaviors displayed by SHR [Spontaneously Hypertensive Rats] are differently altered by cannabinoid and vanilloid drugs when compared to control animals and suggest the endocannabinoid and the vanilloid systems as a potential target for the treatment of schizophrenia.”

Effects of cannabinoid and vanilloid drugs on positive and negative-like symptoms on an animal model of schizophrenia: The SHR strain.
Almeida V, Peres FF, Levin R, Suiama MA, Calzavara MB, Zuardi AW, Hallak JE, Crippa JA, Abílio VC.
Schizophr Res. 2014 Feb 17. pii: S0920-9964(14)00062-0. doi: 10.1016/j.schres.2014.01.039. [Epub ahead of print]
PMID: 24556469 [PubMed - as supplied by publisher]

IV. Serotonin, Opioid, and Dopamine Systems and CS
“In this review we highlight the evidence for the physiological role of such constitutive GPCR [G protein-coupled receptor] activity (in particular for cannabinoid 1, serotonin 2C and mu-opioid receptors) in the ventral tegmental area and in its output regions like the nucleus accumbens. We also address the behavioral relevance of constitutive GPCR signaling and discuss the repercussions of its abolition in dopamine-related psychiatric diseases.”

The vital role of constitutive GPCR activity in the mesolimbic dopamine system.
Meye FJ, Ramakers GM, Adan RA.
Transl Psychiatry. 2014 Feb 11;4:e361. doi: 10.1038/tp.2013.130.
PMID: 24518399 [PubMed - in process]

V. Sleep, Systems and CS
“Overall, these findings demonstrate that the EC [Endo-Cannabinoid] system actively regulates cortical up-states and important features of NREM sleep such as its duration and low frequency cortical oscillations.”

Endocannabinoid Modulation of Cortical Up-States and NREM Sleep.
Pava MJ, den Hartog CR, Blanco-Centurion C, Shiromani PJ, Woodward JJ.
PLoS One. 2014 Feb 10;9(2):e88672. doi: 10.1371/journal.pone.0088672. eCollection 2014.
PMID: 24520411 [PubMed - in process] Free PMC Article

VI. Central Nervous System and CS
“In the present study, we discovered that 2-AG significantly protects CN neurons in culture against lipopolysaccharide (LPS)-induced inflammatory response.”

Endocannabinoid 2-Arachidonylglycerol Protects Primary Cultured Neurons Against LPS-Induced Impairments in Rat Caudate Nucleus.
Lu Y, Peng F, Dong M, Yang H.
J Mol Neurosci. 2014 Feb 9. [Epub ahead of print]
PMID: 24510751 [PubMed - as supplied by publisher]

VII. Nervous System (Alzheimer’s/Dementia) and CS
“The altered CB1 levels appear, rather, to be age-and/or pathology-dependent, indicating an involvement of the endocannabinoid system in AD pathology and supporting the ECS as a potential novel therapeutic target for treatment of AD.”

Altered Expression of the CB1 Cannabinoid Receptor in the Triple Transgenic Mouse Model of Alzheimer's Disease.
Bedse G, Romano A, Cianci S, Lavecchia AM, Lorenzo P, Elphick MR, Laferla FM, Vendemiale G, Grillo C, Altieri F, Cassano
T, Gaetani S.
J Alzheimers Dis. 2014 Feb 4. [Epub ahead of print]
PMID: 24496074 [PubMed - as supplied by publisher]

~.~
February's Video
What if Cannabinoids in Cannabis Cured Cancer & Other Diseases?

Posted by bwb.

0 Comments

Indiscernible Cannabinoid Science ~ Publius’ January 2014 Roundup

1/30/2014

0 Comments

The Cannabis Papers: A citizen’s guide to cannabinoids (2011)
by Publius

Here are a few recent 2013-14 findings on how cannabinoids modulate homeostasis and other systems in our bodies: the roundup links to seven recent PubMed articles on the central nervous, reproductive, neuromodulatory, limbic and opioid systems.

I. Nervous System (Alzheimer’s/Dementia) and CS
“The results confirm the constitutive role of the CB2 receptor system both in reducing amyloid plaque pathology in AD [Alzheimer’s disease] and also support the potential of cannabinoid therapies targeting CB2 to reduce Aβ; however, the results suggest that interventions may have a divergent effect on tau pathology.”

CB2 Receptor Deficiency Increases Amyloid Pathology and Alters Tau Processing in a Transgenic Mouse Model of Alzheimer's Disease.
Koppel J, Vingtdeux V, Marambaud P, D'abramo C, Jimenez H, Stauber M, Friedman R, Davies P.
Mol Med. 2013 Nov 8;19:357-64. doi: 10.2119/molmed.2013.00140.
PMID: 24408112 [PubMed - in process] Free PMC Article

II. Reproductive System (Male) and CS
“Together with their receptors and metabolic enzymes, they form the "endocannabinoid system" (ECS). In male reproductive tracts, they affect Sertoli cell activities, Leydig cell proliferation, germ cell differentiation, sperm motility, capacitation, and acrosome reaction.”

The Endocannabinoid System and Spermatogenesis.
Grimaldi P, Di Giacomo D, Geremia R.
Front Endocrinol (Lausanne). 2013 Dec 16;4:192. eCollection 2013. Review.
PMID: 24379805 [PubMed - as supplied by publisher] Free PMC Article

III. Neuromodulatory System and CS
“Emerging findings suggest the existence of a cross-talk between hypocretinergic and endocannabinoid systems. Although few studies have examined this relationship, the apparent overlap observed in the neuroanatomical distribution of both systems as well as their putative functions strongly point to the existence of such cross-modulation.”

Cannabinoid-hypocretin cross-talk in the central nervous system : what we know so far.
Flores A, Maldonado R, Berrendero F.
Front Neurosci. 2013 Dec 20;7:256. eCollection 2013. Review.
PMID: 24391536 [PubMed - as supplied by publisher] Free PMC Article

IV. Limbic System (Emotions) and CS
"Based on the evidence reviewed here, we propose that the endocannabinoid system is an emotional buffer that moderates the effects of environmental context and stress on cognitive processes."

The endocannabinoid system: An emotional buffer in the modulation of memory function.
Morena M, Campolongo P.
Neurobiol Learn Mem. 2013 Dec 29. pii: S1074-7427(13)00266-9. doi: 10.1016/j.nlm.2013.12.010. [Epub ahead of print]
PMID: 24382324 [PubMed - as supplied by publisher]

V. Central Nervous System (Nicotine/Acetylcholine) and CS
“Furthermore, it seems that there is a functional interaction between the BLA cannabinoid receptors and nicotine in producing the rewarding effects.”

Basolateral amygdala CB1cannabinoid receptors mediate nicotine-induced place preference.
Hashemizadeh S, Sardari M, Rezayof A.
Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jan 24. pii: S0278-5846(14)00011-6. doi: 10.1016/j.pnpbp.2014.01.010. [Epub ahead of print]
PMID: 24468643 [PubMed - as supplied by publisher]

VI. Homeostasis and the CS
“The endocannabinoid system is present in stress-responsive neural circuits and it is emerging as a homeostatic system.”

Regulatory role of the Cannabinoid-2 receptor in stress-induced neuroinflammation in mice.
Zoppi S, Madrigal JL, Caso JR, García-Gutiérrez MS, Manzanares J, Leza JC, García-Bueno B.
Br J Pharmacol. 2014 Jan 28. doi: 10.1111/bph.12607. [Epub ahead of print]
PMID: 24467609 [PubMed - as supplied by publisher]

VII. Opioid System and CS
“These results enhance our understanding of the mechanisms involved in the peripheral effect of crotalphine an antinociceptive peptide, as well as the interaction between the opioid and cannabinoid systems.”

Peripheral interactions between cannabinoid and opioid systems contribute to the antinociceptive effect of crotalphine.
Machado FC, Zambelli VO, Fernandes AC, Heimann AS, Cury Y, Picolo G.
Br J Pharmacol. 2014 Feb;171(4):961-72. doi: 10.1111/bph.12488.
PMID: 24460677 [PubMed - in process]

~
Bryan w. Brickner

0 Comments

Life Serotonin Supplementation Update: UK Microdosing LSD and Serotonin Receptors

Homeostasis: Publius’ (Ultralow) THC Political Cannabinoid Science

Homeostasis: Publius’ Alcohol Political Cannabinoid Science

Alzheimer’s, Cancer and Homeostatic Cannabinoid Science

Passing the Alzheimer’s Test and One’s Cannabinoid System ~ An Update

Indiscernible Cannabinoid Science ~ Publius’ March 2014 Roundup

Passing the Alzheimer’s Test Involves One’s Cannabinoid System

Indiscernible Cannabinoid System Science ~ Publius’ February 2014 Roundup

Indiscernible Cannabinoid Science ~ Publius’ January 2014 Roundup

Author

Archives

Categories